tirzepatide cardiovascular outcome trial outcomes results july 2025 In patients with type 2 diabetes and atherosclerotic cardiovascular tirzepatide cardiovascular outcomes trial results

Some users experience unwanted facial hair growth or systemic effects like heart palpitations

Ozempic is FDA-approved for type 2 diabetes management, while Wegovy is FDA-approved for chronic weight management in adults with obesity or overweight

Key Takeaway: Prior authorization for weight-loss GLP-1s usually requires a documented BMI of 30 or higher, or 27 with comorbidities, plus a 6-month lifestyle intervention history

Glucagon receptor activation may increase energy expenditure

(29) While this cannot be directly extrapolated to human outcomes, it does provide the beginnings of research that could be promising for reducing joint infections